Literature DB >> 18158219

Neurodevelopmental and neurodegenerative diseases - is there a pathophysiological link? Attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis as examples.

D Lule1, A C Ludolph, A G Ludolph.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD), the most common neurobehavioural disorder and amyotrophic lateral sclerosis (ALS), the most common adult motoneuron disease, may be two distinct entities on first sight. This paper aims to highlight parallels concerning clinical features and neurobiology. The presence of increased physical and psychological activity and largely non-progressive frontal dysfunction associated with impaired executive control and decreased attention are characteristic clinical features of both, ADHD and ALS. At the neurobiological level, there is evidence for hyperactivity in the glutamatergic system and a - potentially related - dopaminergic hypoactivity in ADHD and ALS. The clinical features of ALS resembling ADHD are particularly characteristic for the premorbid stage of the patient. Therefore, we hypothesize that clinical features of ADHD may be a risk factor for the development of ALS. This hypothesis is currently of unknown pathogenetic, but of potential future therapeutic relevance. Our hypothesis of a link between ADHD and ALS could also be considered as an example how research on neurodevelopmental diseases might influence the understanding and possibly the prevention and treatment of neurodegenerative diseases.

Entities:  

Mesh:

Year:  2007        PMID: 18158219     DOI: 10.1016/j.mehy.2007.11.002

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.

Authors:  Andrea G Ludolph; Patrick T Udvardi; Ulrike Schaz; Carolin Henes; Oliver Adolph; Henry U Weigt; Joerg M Fegert; Tobias M Boeckers; Karl J Föhr
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  Emotional adjustment in amyotrophic lateral sclerosis (ALS).

Authors:  Dorothée Lulé; Sandra Pauli; Ertan Altintas; Ulrike Singer; Thomas Merk; Ingo Uttner; Niels Birbaumer; Albert C Ludolph
Journal:  J Neurol       Date:  2011-08-02       Impact factor: 4.849

3.  Attention deficit hyperactivity disorder (ADHD): from a childhood neuropsychiatric disorder to an adult condition.

Authors:  Rita Vadalà; Elisabetta Giugni; Anna Pichiecchio; Umberto Balottin; Stefano Bastianello
Journal:  Funct Neurol       Date:  2011 Jul-Sep

Review 4.  Factors Influencing Clinical Correlates of Chronic Traumatic Encephalopathy (CTE): a Review.

Authors:  Breton M Asken; Molly J Sullan; Aliyah R Snyder; Zachary M Houck; Vaughn E Bryant; Loren P Hizel; Molly E McLaren; Duane E Dede; Michael S Jaffee; Steven T DeKosky; Russell M Bauer
Journal:  Neuropsychol Rev       Date:  2016-08-25       Impact factor: 7.444

5.  Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.

Authors:  Malcolm Proudfoot; Gustavo Rohenkohl; Andrew Quinn; Giles L Colclough; Joanne Wuu; Kevin Talbot; Mark W Woolrich; Michael Benatar; Anna C Nobre; Martin R Turner
Journal:  Hum Brain Mapp       Date:  2016-09-13       Impact factor: 5.038

6.  Exome sequencing to identify de novo mutations in sporadic ALS trios.

Authors:  Alessandra Chesi; Brett T Staahl; Ana Jovičić; Julien Couthouis; Maria Fasolino; Alya R Raphael; Tomohiro Yamazaki; Laura Elias; Meraida Polak; Crystal Kelly; Kelly L Williams; Jennifer A Fifita; Nicholas J Maragakis; Garth A Nicholson; Oliver D King; Robin Reed; Gerald R Crabtree; Ian P Blair; Jonathan D Glass; Aaron D Gitler
Journal:  Nat Neurosci       Date:  2013-05-26       Impact factor: 24.884

7.  Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.

Authors:  Patrick T Udvardi; Karl J Föhr; Carolin Henes; Stefan Liebau; Jens Dreyhaupt; Tobias M Boeckers; Andrea G Ludolph
Journal:  Drug Des Devel Ther       Date:  2013-12-04       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.